New hope for SMA patients: early access to apitegromab
NCT ID NCT06877689
First seen May 04, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This program gives eligible patients with spinal muscular atrophy (SMA) early access to the investigational drug apitegromab before it is officially approved. Participants must be at least 2 years old and have a confirmed SMA diagnosis. A doctor will decide if the potential benefits outweigh the risks for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.